Severe hypertriglyceridemia and hypercholesterolemia accelerating renal injury: A novel model of type 1 diabetic hamsters induced by short-term high-fat / high-cholesterol diet and low-dose streptozotocin

BMC Nephrology

Volumn 16, Issue 1, 2015, Pages

  He, Liang ^a   Hao, Lili ^b   Fu, Xin ^a   Huang, Mingshu ^a   Li, Rui ^c,d  

^a National Shanghai Center for New Drug Safety Evaluation and Research   (China)

^b SOUTHWEST UNIVERSITY FOR NATIONALITIES   (China)

^c State Key Laboratory Breeding Base for Zhejiang Sustainable Plant Pest Control   (China)

^d INSTITUTE OF PLANT PROTECTION AND MICROBIOLOGY   (China)

Author keywords

Diabetes; Hamsters; High cholesterol; High fat; Hypercholesterolemia; Hyperlipidemia; Hypertriglyceridemia; Renal injury; Streptozotoncin

Indexed keywords

CHOLESTEROL; COLLAGEN; CREATININE; GLIPIZIDE; GLUCOSE; INSULIN; INTERLEUKIN 6; MESSENGER RNA; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; CHOLESTEROL INTAKE; GLUCOSE BLOOD LEVEL; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE SEVERITY; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HAMSTER MODEL; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY HYPERTROPHY; KIDNEY INJURY; LIPID DIET; LIPID STORAGE; MALE; NONHUMAN; PROTEIN URINE LEVEL; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SURFACE AREA; SYRIAN HAMSTER; UPREGULATION; URINARY EXCRETION; WEIGHT REDUCTION; ANIMAL; CHOLESTEROL INTAKE; DIABETIC NEPHROPATHY; DISEASE MODEL; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HAMSTER; KIDNEY; MESOCRICETUS; METABOLISM;

ANIMALS; BLOOD GLUCOSE; CHOLESTEROL, DIETARY; CREATININE; CRICETINAE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INTERLEUKIN-6; KIDNEY; MALE; MESOCRICETUS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINURIA; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84929150066     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-015-0041-5     Document Type: Article

References (48)

1. Mahamuni SP, Khose RD, Menaa F, Badole SL. Therapeutic approaches to drug targets in hyperlipidemia. Biogeosciences. 2012;2:137-46.
2. Rosario RF, Prabhakar S. Lipids and diabetic nephropathy. Curr Diab Rep. 2006;6(6):455-62.
3. Kim DM, Ahn CW, Park JS, Cha BS, Lim SK, Kim KR, et al. An implication of hypertriglyceridemia in the progression of diabetic nephropathy in metabolically obese, normal weight patients with type 2 diabetes mellitus in Korea. Diabetes Res Clin Pract. 2004;66 Suppl 1:S169-72.
4. Prakash J. Dyslipidemia in diabetic kidney disease. Clinical Queries: Nephrology. 2012;0102:115-8.
5. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 2005;352(11):1138-45.
6. Bailie GR, Uhlig K, Levey AS. Clinical practice guidelines in nephrology: evaluation, classification, and stratification of chronic kidney disease. Pharmacotherapy. 2005;25(4):491-502.
7. Molitch ME DR, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW. Nephropathy in diabetes. Diabetes Care. 2004;27 Suppl 1:S79-83.
8. Vincent AM, Hinder LM, Pop-Busui R, Feldman EL. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst. 2009;14(4):257-67.
9. Clemens A, Siegel E, Gallwitz B. Global risk management in type 2 diabetes: blood glucose, blood pressure, and lipids-update on the background of the current guidelines. Exp Clin Endocrinol Diabetes. 2004;112(9):493-503.
10. Gordon Smith A, Robinson Singleton J. Idiopathic neuropathy, prediabetes and the metabolic syndrome. J Neurol Sci. 2006;242(1-2):9-14.
11. Brosius 3rd FC, Alpers CE, Bottinger EP, Breyer MD, Coffman TM, Gurley SB, et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol. 2009;20(12):2503-12.
12. Allen TJ, Cooper ME, Lan HY. Use of genetic mouse models in the study of diabetic nephropathy. Curr Atheroscler Rep. 2004;6(3):197-202.
13. Williams KJ, Qiu G, Usui HK, Dunn SR, McCue P, Bottinger E, et al. Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol. 2007;171(5):1441-50.
14. Shimamura T, Morrison AB. A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol. 1975;79(1):95-106.
15. Shobeiri N, Adams MA, Holden RM. Vascular calcification in animal models of CKD: A review. Am J Nephrol. 2010;31(6):471-81.
16. Spencer MW, Muhlfeld AS, Segerer S, Hudkins KL, Kirk E, LeBoeuf RC, et al. Hyperglycemia and hyperlipidemia act synergistically to induce renal disease in LDL receptor-deficient BALB mice. Am J Nephrol. 2004;24(1):20-31.
17. Yoshida M, Kimura H, Kyuki K, Ito M. Effect of combined vitamin E and insulin administration on renal damage in diabetic rats fed a high cholesterol diet. Biol Pharm Bull. 2005;28(11):2080-6.
18. Wang PR, Guo Q, Ippolito M, Wu M, Milot D, Ventre J, et al. High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists. Eur J Pharmacol. 2001;427(3):285-93.
19. Ontko JA, Cheng Q, Yamamoto M. Metabolic factors underlying high serum triglycerides in the normal hamster. J Lipid Res. 1990;31(11):1983-92.
20. Matthan NR, Dillard A, Lecker JL, Ip B, Lichtenstein AH. Effects of dietary palmitoleic acid on plasma lipoprotein profile and aortic cholesterol accumulation are similar to those of other unsaturated fatty acids in the F1B golden Syrian hamster. J Nutr. 2009;139(2):215-21.
21. Rabinovitch A, Suarez-Pinzon WL, Sorensen O. Interleukin 12 mRNA expression in islets correlates with beta-cell destruction in NOD mice. J Autoimmun. 1996;9(5):645-51.
22. Lee EA, Seo JY, Jiang Z, Yu MR, Kwon MK, Ha H, et al. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney. Kidney Int. 2005;67(5):1762-71.
23. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911-7.
24. Fink L, Seeger W, Ermert L, Hanze J, Stahl U, Grimminger F, et al. Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med. 1998;4(11):1329-33.
25. Song G, Liang H, Yilei D, George L. Mechanisms underlying different responses of plasma triglyceride to high-fat diets in hamsters and mice: Roles of hepatic MTP and triglyceride secretion. Biochem Bioph Res. 2010;398:619-26.
26. Dorfman SE, Smith DE, Osgood DP, Lichtenstein AH. Study of diet-induced changes in lipoprotein metabolism in two strains of Golden-Syrian hamsters. J Nutr. 2003;133(12):4183-8.
27. Sugano M, Yamato H, Hayashi T, Ochiai H, Kakuchi J, Goto S, et al. High-fat diet in low-dose-streptozotocin-treated heminephrectomized rats induces all features of human type 2 diabetic nephropathy: a new rat model of diabetic nephropathy. Nutr Metab Cardiovasc Dis. 2006;16(7):477-84.
28. Popov D, Simionescu M, Shepherd PR. Saturated-fat diet induces moderate diabetes and severe glomerulosclerosis in hamsters. Diabetologia. 2003;46(10):1408-18.
29. Danda RS, Habiba NM, Rincon-Choles H, Bhandari BK, Barnes JL, Abboud HE, et al. Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int. 2005;68(6):2562-71.
30. Wang Z, Jiang T, Li J, Proctor G, McManaman JL, Lucia S, et al. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes. 2005;54(8):2328-35.
31. Wei P, Lane PH, Lane JT, Padanilam BJ, Sansom SC. Glomerular structural and functional changes in a high-fat diet mouse model of early-stage Type 2 diabetes. Diabetologia. 2004;47(9):1541-9.
32. Loredana Marcovecchio M, Neil Dalton R, Toby Prevost A, Acerini CL, Barrett TG, Cooper JD, et al. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care. 2009;32(4):658-63.
33. Raile K, Galler A, Hofer S, Herbst A, Dunstheimer D, Busch P, et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care. 2007;30(10):2523-8.
34. Basciano H, Miller AE, Naples M, Baker C, Kohen R, Xu E, et al. Metabolic effects of dietary cholesterol in an animal model of insulin resistance and hepatic steatosis. Am J Physiol Endocrinol Metab. 2009;297(2):E462-73.
35. Srinivasan K, Patole PS, Kaul CL, Ramarao P. Reversal of glucose intolerance by by pioglitazone in high fat diet-fed rats. Methods Find Exp Clin Pharmacol. 2004;26(5):327-33.
36. Colca JR, Dailey CF, Palazuk BJ, Hillman RM, Dinh DM, Melchior GW, et al. Pioglitazone hydrochloride inhibits cholesterol absorption and lowers plasma cholesterol concentrations in cholesterol-fed rats. Diabetes. 1991;40(12):1669-74.
37. Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA, et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol. 2000;11(4):669-83.
38. Young NL, Lopez DR, McNamara DJ. Contributions of absorbed dietary cholesterol and cholesterol synthesized in small intestine to hypercholesterolemia in diabetic rats. Diabetes. 1988;37(8):1151-6.
39. Logan JL. Studies on the impact of dietary fat composition on proteinuria in diabetic rats. Diabetes Res Clin Pract. 1996;33(1):21-9.
40. Cooper ME, Vranes D, Vranes DA, Allen TJ, Panagiotopoulos S, Komers R, et al. The effects of dietary cholesterol on experimental diabetic nephropathy. Diabetes Res. 1993;22(4):159-69.
41. Hahn T, Yao S, Dunford LM, Thomas J, Lohr J, Arora P, et al. A comparison of measured creatinine clearance versus calculated glomerular filtration rate for assessment of renal function before autologous and allogeneic BMT. Biol Blood Marrow Transplant. 2009;15(5):574-9.
42. Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol. 2004;24(1):46-53.
43. Sun L, Halaihel N, Zhang W, Rogers T, Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem. 2002;277(21):18919-27.
44. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem. 2002;277(22):19353-7.
45. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes. 2002;51(10):3090-4.
46. Wang JJ, Zhang SX, Mott R, Chen Y, Knapp RR, Cao W, et al. Anti-inflammatory effects of pigment epithelium-derived factor in diabetic nephropathy. Am J Physiol Renal Physiol. 2008;294(5):F1166-73.
47. Shum L, Rabie AB, Hagg U. Vascular endothelial growth factor expression and bone formation in posterior glenoid fossa during stepwise mandibular advancement. Am J Orthod Dentofacial Orthop. 2004;125(2):185-90.
48. Lindenmeyer MT, Kretzler M, Boucherot A, Berra S, Yasuda Y, Henger A, et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol. 2007;18(6):1765-76.